Most Read This Week
- Comparison of First-Line Chemotherapy Regimens in Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- Next-Generation Oral SERD Camizestrant vs Fulvestrant in Postmenopausal ER+/HER2− Advanced Breast Cancer
- The Lancet Breast Cancer Commission: Evidence-Based Roadmap to Address Urgent Global Breast Cancer Challenges
- Real-World Outcomes in Patients With Brain Metastases Secondary to HR+/HER2− MBC Treated With Abemaciclib and Local Intracranial Therapy
- Neoadjuvant Chemoradiation Followed by FOLFIRINOX for Stage II/III Rectal Cancer
Recently Updated
- Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery in Patients With Stage III Soft Tissue Sarcoma of the Extremity
- Vaccination of 27- to 45-Year-Olds Against HPV Is Less Cost-Effective
- Racial, Ethnic Disparities Seen in Mortality With Early-Onset Colorectal Cancer
- Characteristics Differ for Melanomas in Children, Teens, Young Adults
- Comparison of First-Line Chemotherapy Regimens in Unresectable Locally Advanced or Metastatic Pancreatic Cancer